Project Grant R01HL176777
- This federal Project Grant award, titled "Regulation of Primary and Secondary Alveologenesis by FGF Signaling Pathways", was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The $740,317 award supports research conducted by The Washington University in St. Louis, Missouri to advance scientific understanding of alveolar development and lung regeneration. The research aims to investigate the mechanisms that regulate...
- This federal Project Grant award of $761,017.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to identify and characterize human pulmonary neuroendocrine progenitor cells (NEPRs) within the distal airways and their role in airway repair and injury response. The research aims to build a foundational understanding of the anatomical distribution, molecular profiles, and functional characteristics of these rare human lung cell...
- This $480,990 Project Grant awarded by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) aims to establish the central role of a recently identified lung cell type, "aerocytes," in regulating alveolar regeneration following lung injury. The research proposal has two key objectives: Investigate the role of aerocyte-derived R-spondin3 in lung growth and recovery using animal studies within disease-related lung injury models....
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,659,996.00 to the University of Southern California (USC) to investigate the role of the NF-kappaB modulator PDLIM2 in alveolar macrophages and its impact on lung innate immunity, inflammation, and diseases. The research aims to elucidate how alveolar macrophages, which are critical for lung defense, can promote lung cancer and increase vulnerability to...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $701,795 to The Trustees of the University of Pennsylvania to conduct research aimed at defining the cardinal functions of lung progenitors during regeneration. The 4-year project, which began in September 2025, utilizes a multi-modal approach including cell lineage tracing, single-cell analysis, histological spatial analysis, and cross-species comparison to...
- The Project Grant award titled "Alveolar Epithelial Stress Signaling in Lung Fibrosis" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $683,564.00 over the period of Jul 1, 2025 to Mar 31, 2030. The award supports comprehensive research focused on understanding the role of aberrant alveolar epithelial cells in the pathogenesis of pulmonary fibrosis, a devastating and progressive lung disease. The research aims to investigate...
- This federal Project Grant award of $811,370.00, provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to study the role of the Hippo-YAP/TAZ signaling pathway in regulating alveolar epithelial cell regeneration during lung repair. The research aims to determine the critical cellular and molecular mechanisms that facilitate normal alveolar repair and regeneration, with the overarching hypothesis that dynamic,...
- This federal Project Grant award of $248,999 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research on mesenchymal cell plasticity and signaling in lung regeneration. The award aims to examine how specific mesenchymal cell lineages establish and maintain maladaptive epithelial regeneration after severe lung injury, such as from influenza or COVID-19. Key objectives include investigating the proliferation, plasticity, and Notch...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research into the role of post-transcriptional RNA modifications in lung development and regeneration. The $768,985 award, effective September 1, 2025 through June 30, 2029, will enable researchers at Columbia University's Health Sciences Division to study how the METTL3/14 complex-mediated RNA modifications, including on the SOX9 transcript, regulate lung...
- The federal Project Grant award of $108,978.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the mechanisms underlying the age-related decline in the regenerative capacity of alveolar type 2 (AT2) cells in the lung. The principal investigator and research team at the Harvard T.H. Chan School of Public Health will conduct studies to determine whether elevated interferon gamma (IFNG) levels and changes in resident...
This federal Project Grant award for $637,913, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research by the University of Southern California (USC) to investigate the role of "transitional alveolar epithelial cells" in lung development and regeneration. The goal is to better understand the mechanisms underlying the alveolar epithelial cell differentiation process during normal lung development, as well as in response to injury, with a focus on immature lungs in preterm infants. The award period runs from Sep 10, 2025 to Jun 30, 2029 and will allow USC researchers to conduct this translational research project aimed at advancing scientific knowledge about potential regenerative capacity in the lungs of preterm infants.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $637.9k | 9/9/25 |